Professor of Surgery, University Tex Houston
General Surgery
Dr. Lee M. Ellis, MD
|
|
Give Review
Ellis practices General Surgery. He graduated from University of Virginia School of Medicine. He received awards:"America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Fellow (FACS)". Doctor Lee M. Ellis, MD is also a published MD. He has 102 paper published. The most recent paper is: Intracrine VEGF Signaling Mediates the Activity of Pro-survival Pathways in Human Colorectal Cancer Cells. He accepts all Medicare patients.
Publications
- A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
- CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer-From Concept to Practice.
- Criminality and the 2D:4D ratio: testing the prenatal androgen hypothesis.
- The requirement for freshly isolated human colorectal Cancer (CRC) cells in isolating CRC stem cells.
- Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
- Pragmatic issues in biomarker evaluation for targeted therapies in Cancer.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- Therapeutic Silencing of KRAS using Systemically DeLivered siRNAs.
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes.
- ATP Citrate Lyase Mediates Resistance of Colorectal Cancer Cells to SN38.
- miR-203 induces oxaliplatin resistance in colorectal Cancer cells by negatively regulating ATM kinase.
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal Cancer who undergo resection after ...
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1.
- Clinical Cancer advances 2012: annual report on progress against Cancer from the american society of clinical oncology.
- Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies.
- Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series.
- Morbidity of Staged Proctectomy After Hepatectomy for Colorectal Cancer: A Matched Case-Control Analysis.
- Overexpression of Snail induces epithelial-mesenchymal transition and a Cancer stem cell-like phenotype in human colorectal Cancer cells.
- Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in ColoRectal Adenocarcinoma Patients.
- Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced coloRectal adenocarcinoma.
- Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer.
- A novel platform for detection of CK+ and CK- CTCs.
- Intracellular ATP levels are a pivotal determinant of chemoresistance in colon Cancer cells.
- APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal Cancer and predicts human hepatic metastasis.
- Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors.
- Circulating angiogenic factors, tumor cells, and outcome after resection of metastatic colorectal Cancer--what does it mean?
- Targeted therapies: Peaking beneath the surface of recent bevacizumab trials.
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
- Neuropilin-2 Mediated ?-Catenin Signaling and Survival in Human Gastro-Intestinal Cancer Cell Lines.
- Varying opinions on the authenticity of a human midgut carcinoid cell line--letter.
- Finding the tumor copycat. Therapy fails, patients don't.
- Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal Cancer.
- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal Cancer: efficacy and circulating angiogenic biomarkers associated with...
- Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/{beta}-catenin Crosstalk Leads to Tumor Cell Death.
- Resistance to Targeted Therapies: Refining AntiCancer Therapy in the Era of Molecular Oncology.
- Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.
- Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal Cancer in the liver.
- Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
- Targeting tumor angiogenesis.
- Functional significance of VEGFR-2 on ovarian Cancer cells.
- Chemoresistant colorectal Cancer cells, the Cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.
- Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma.
- Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic coloRectal metastases.
- Bevacizumab beyond progression: does this make sense?
- Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal Cancer liver metastases.
- Pathways mediating resistance to Vascular endothelial growth factor-targeted therapy.
- Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study.
- Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal Cancer cells.
- Targeting angiogenesis driven by Vascular endothelial growth factors using antibody-based therapies.
- Effect of molecular therapeutics on Liver regeneration in a murine model.
- Impact of vessel maturation on antiangiogenic therapy in ovarian Cancer.
- Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.
- Therapeutic targeting of neuropilin-2 on coloRectal carcinoma cells implanted in the murine liver.
- Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
- Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for coloRectal liver metastases.
- Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
- The development and characterization of a human midgut carcinoid cell line.
- Overexpression of PDGF-BB decreases colorectal and pancreatic Cancer growth by increasing tumor pericyte content.
- Targeted therapy trials: approval strategies, target validation, or helping patients?
- Mammalian target of rapamycin is activated in human gastric Cancer and serves as a target for therapy in an experimental model.
- Tyrosine kinase receptor RON in human pancreatic Cancer: expression, function, and validation as a target.
- Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal Cancer.
- Production of VEGF165 by Ewing's Sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.
- Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
- Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal Cancer cell lines.
- Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells.
- Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesoRectal excision...
- Results of a single-center experience with resection and ablation for sarcoma metastatic to the Liver.
- The role of neuropilins in Cancer.
- Roles of nitric oxide synthase inhibition and Vascular endothelial growth factor receptor-2 inhibition on Vascular morphology and function in an in vivo model of pancr...
- Accuracy of preoperative imaging of hepatic Tumors with helical computed tomography.
- Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic Cancer.
- Debunking dogma: surgery for four or more coloRectal liver metastases is justified.
- Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor Malignancies.
- Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.
- Upregulation of neuropilin-1 by basic fibroblast growth factor enhances Vascular smooth muscle cell migration in response to VEGF.
- Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model.
- Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration ...
- Surgical resection after downsizing of coloRectal liver metastasis in the era of bevacizumab.
- Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.
- Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
- Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
- Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors.
- Improving deLivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.
- RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
- Role of the Vascular endothelial growth factor pathway in tumor growth and angiogenesis.
- Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.
- Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
- Angiogenesis and its role in coloRectal tumor and metastasis formation.
- Epidermal growth factor receptor in tumor angiogenesis.
- Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
- Preclinical data targeting vascular endothelial growth factor in colorectal Cancer.
- The Vascular endothelial growth factor family and its receptors.
- Regulation of vascular endothelial growth factor expression in human gastric Cancer cells by interleukin-1beta.
- ZD6474, a Vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhi...
- Long-term survival after an aggressive surgical approach in patients with breast Cancer hepatic metastases.
- Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
- Current overview of angiogenesis inhibitors.
- Intracrine VEGF Signaling Mediates the Activity of Pro-survival Pathways in Human Colorectal Cancer Cells.
Schools
Univ Of Va Sch Of Med Hlth Sys
University Fla Shands Hospital
MD Anderson Canc Center
Procedures Preformed
- Colectomy
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- Laparotomy
- Lymph Node Biopsy or Excision
Conditions Treated
- Abdominal Pain
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Atelectasis
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FACS)
Education
-
University of Virginia School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1952409161 | |
| NPPES Provider LastName | ELLIS | |
| NPPES Provider FirstName | LEE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 11.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952409161 |
| Last Name Of The Provider | ELLIS |
| First Name Of The Provider | LEE |
| View All |
Similar Doctors
|
Dr. Arlene E. Ricardo, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert S. Bloss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry M. Kuerer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean Bismuth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hiram L. Brockman, MD |
|
|
Dr. Ramesh K. Srungaram, MD |
|
|
Dr. Kunjeelal Chandrakar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Courtney J. Gemmato, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine M. Hambleton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Kristina M. Scroggins |